Brief: Akoya’s Spatial Proteomics Platforms Selected For Use By UK-Based Manifest Consortium To Cancer Immunotherapy
07/10/2024 13:20
Oct 7 (Reuters) - Akoya Biosciences Inc AKYA.O :
* AKOYA’S LEADING SPATIAL PROTEOMICS PLATFORMS SELECTED FOR
USE BY
GROUND-BREAKING UK-BASED MANIFEST CONSORTIUM TO REVOLUTIONIZE
CANCER IMMUNOTHERAPY
Source text for Eikon: ID:nGNX49W4zF
Further company coverage: AKYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akoya Biosciences
See all newsBrief: Akoya Biosciences Inc - On May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing
Akoya Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Akoya Biosciences Q1 Gross Margin 59.3%
Akoya Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Leerink Partners downgrades Quanterix to 'market perform' on Akoya deal risks